Prevention through vaccination remains critical
In South Korea, a quiet but consequential expansion of protection has been granted to younger vulnerable adults — those whose chronic conditions make a common respiratory virus far more dangerous than it appears. The country's drug regulator has approved GSK's Arexvy RSV vaccine for high-risk adults aged 18 to 49, completing a phased rollout that now covers all at-risk adults regardless of age. Where medicine once drew its lines by decade of life, this decision acknowledges that vulnerability is defined not by age alone, but by the body's particular relationship with illness.
- RSV is deceptively ordinary for healthy people but can multiply hospitalization risk by as much as thirteen times for those living with COPD, heart failure, or diabetes — a hidden danger hiding in plain sight.
- Until now, younger adults with serious chronic conditions occupied a gap in Korea's RSV vaccine coverage, left unprotected despite facing risks comparable to the elderly populations already approved.
- A global phase 3b trial demonstrated that adults aged 18 to 49 with chronic conditions mounted immune responses equal to those of older populations, providing the scientific foundation regulators needed to act.
- With no specific treatment available for adult RSV infection, this approval shifts the entire burden of defense onto prevention — making the timing of vaccination before late-summer seasonal peaks a matter of clinical urgency.
- A single dose of Arexvy now offers protection spanning three RSV seasons, and GSK has pledged to work with Korean health authorities to translate regulatory approval into timely, widespread vaccination among at-risk communities.
South Korea's Ministry of Food and Drug Safety has approved an expanded use of GSK's Arexvy RSV vaccine for adults aged 18 to 49 who carry elevated risk due to chronic illness — completing a phased rollout that began with adults 60 and older in December 2024 and extended to high-risk adults aged 50 to 59 in November 2025. The decision closes the final gap, bringing RSV protection to the full spectrum of vulnerable adults across all age groups.
The at-risk category encompasses people living with chronic respiratory or heart disease, diabetes with complications, end-stage kidney disease, and moderate to severe immune disorders. For these individuals, RSV is far from the mild inconvenience it represents for healthy adults. Research shows the virus raises hospitalization risk two to four times in asthma patients, three to thirteen times in those with COPD, and eight times in people with heart failure. Among those already hospitalized, the risk of a COPD flare-up within a week rises roughly 23-fold.
The expanded approval rests on a global phase 3b trial showing that younger at-risk adults produced immune responses non-inferior to those of older populations — a finding that mirrored the safety profile already established in earlier studies. In adults 60 and older, Arexvy demonstrated 82.6% efficacy against RSV-related lower respiratory tract disease, rising to 94.6% among those with at least one underlying condition.
Because no specific adult treatment for RSV exists beyond supportive care, vaccination stands as the primary line of defense. RSV peaks seasonally — typically ahead of influenza — making late summer the critical window for immunization. A single dose of Arexvy has shown sustained protection across three consecutive RSV seasons. GSK Korea said it will work with health authorities and providers to ensure at-risk populations are reached before the next seasonal wave arrives.
South Korea's drug regulator has cleared the way for a respiratory virus vaccine to reach a younger population of vulnerable adults. On Friday, the Ministry of Food and Drug Safety approved an expanded use of GSK's Arexvy for people aged 18 to 49 who face elevated risk from respiratory syncytial virus—a pathogen that causes acute respiratory infection and can turn severe in those with underlying health conditions.
This marks the third phase of Arexvy's rollout in Korea. The vaccine first won approval for all adults 60 and older in December 2024, then expanded to high-risk adults aged 50 to 59 in November 2025. The latest decision fills the gap, now covering the full spectrum of at-risk adults across all age groups. The high-risk category includes people living with chronic respiratory disease, chronic heart disease, diabetes with complications, end-stage kidney disease, and moderate to severe immune system disorders.
The approval rests on data from a global phase 3b clinical trial that tested the vaccine's ability to trigger immune responses in younger adults with chronic medical conditions. Researchers compared how well the vaccine worked in this 18-to-49 age group against results from older populations. The immune responses proved non-inferior—meaning the younger at-risk group mounted defenses comparable to older adults. Safety profiles also aligned with what had been observed in the older population.
In earlier studies of adults 60 and older, Arexvy showed an overall effectiveness of 82.6 percent against lower respiratory tract disease caused by RSV. Among those older adults who had at least one underlying medical condition, effectiveness climbed to 94.6 percent. The virus itself is deceptive: healthy adults often shake off RSV infection with mild symptoms, but for people with chronic conditions, the consequences can be severe. Research shows RSV infection increases hospitalization risk by two to four times in asthma patients, three to thirteen times in those with COPD, eight times in heart failure patients, and 2.4 to 11.4 times in people with diabetes. Among hospitalized RSV patients, the risk of COPD flare-up within a week jumps roughly 23-fold, while the risk of heart failure deterioration rises about 13-fold.
Because no specific treatment exists for RSV infection in adults beyond supportive care, prevention through vaccination becomes the primary defense. The Korean Society of Infectious Diseases recommends RSV vaccination for adults 75 and older and for anyone at high risk of severe disease. RSV circulates year-round but peaks seasonally, typically earlier than influenza, making late summer an optimal window for vaccination.
Arexvy contains an adjuvant—a compound designed to amplify immune response—particularly useful for older adults whose immune systems may be less reactive. A single dose has demonstrated sustained protection across three consecutive RSV seasons. Kwon Hyun-ji, head of GSK Korea's Vaccines Business Unit, described the expanded approval as meaningful because it extends RSV prevention across the entire adult age spectrum. The company said it will work with health authorities and healthcare providers to ensure timely vaccination and build awareness of RSV prevention among at-risk populations.
Notable Quotes
The expanded indication for Arexvy is particularly meaningful because it broadens RSV prevention to high-risk adults across the entire adult age spectrum— Kwon Hyun-ji, head of Vaccines Business Unit at GSK Korea
The Hearth Conversation Another angle on the story
Why does this approval matter now, when RSV has always existed?
Because until recently, there was no vaccine at all. RSV can be devastating for people with chronic conditions—heart disease, COPD, diabetes—but we had no way to prevent it. Now we do, and the data shows it works.
The efficacy numbers are striking—94.6 percent in older adults with underlying conditions. Why so high?
The vaccine was specifically designed with an adjuvant to boost immune response. In older people, immunity naturally weakens, so the adjuvant helps compensate. And the people who benefit most are exactly those whose bodies struggle most—they have the most to gain.
But this approval is for younger people, 18 to 49. Are they really at that much risk?
Only if they have chronic conditions. A healthy 25-year-old won't get seriously ill from RSV. But a 25-year-old with COPD or heart failure? RSV could land them in the hospital. That's who this is for.
The timing of late summer for vaccination—is that just convenience, or does it matter medically?
It matters. RSV outbreaks start earlier than flu season. If you wait until fall, you might miss the window. Late summer gives protection before the surge hits.
One dose for three seasons seems almost too good. How is that possible?
The immune response the vaccine triggers is durable. It doesn't fade quickly like some vaccines do. Three years of protection from a single injection is genuinely significant for people who can't afford to get sick.
What happens to people who don't get vaccinated?
They remain vulnerable. Without treatment options beyond supportive care, RSV infection becomes a serious threat. For someone with heart failure, it could mean hospitalization or worse.